CVAC CureVac
- 2.910
- -0.070-2.35%
- 2.980
- +0.070+2.41%
CureVac News
Deutsche Numis Keeps Their Hold Rating on CureVac (CVAC)
Analysts Conflicted on These Healthcare Names: 4D Molecular Therapeutics (FDMT), Revance Therapeutics (RVNC) and CureVac (CVAC)
Elon Musk Breaks Ranks With GOP By Praising Genetic Engineering Tech That Helped Fight COVID-19: 'Digital Medicine With Incredible Potential'
Tesla CEO Elon Musk does not seem to agree with Republicans at least on one thing. On Wednesday, the billionaire, true to his credentials as a tech pioneer, unequivocally backed the mRNA technology, w
Spirit Airlines Posts Weak Results, Joins Integra LifeSciences, Bowlero And Other Big Stocks Moving Lower On Monday
U.S. stocks were higher, with the Nasdaq Composite gaining over 100 points on Monday.Shares of Spirit Airlines, Inc. (NYSE:SAVE) fell sharply during Monday's session as the company reported a first-qu
CureVac Full Year 2023 Earnings: Misses Expectations
UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating
UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating.
Curevac's Market Forecast Risks: Miscalculations and Trial Participant Challenges Threaten Profitability
Curevac Cut to Market Perform From Outperform by Leerink Partners
Curevac Cut to Market Perform From Outperform by Leerink Partners
Leerink Partners Downgrades CureVac to Market Perform, Lowers Price Target to $4
Leerink Partners analyst Mani Foroohar downgrades CureVac from Outperform to Market Perform and lowers the price target from $12 to $4.
CureVac Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/25/2024 60% Leerink Partners $12 → $4 Downgrades Outperform → Market Perform 04/05/2024 — Guggenheim R
Analysts Offer Insights on Healthcare Companies: CureVac (CVAC) and BioMarin Pharmaceutical (BMRN)
Earnings Call Summary | CureVac(CVAC.US) Q4 2023 Earnings Conference
The following is a summary of the CureVac N.V. (CVAC) Q4 2023 Earnings Call Transcript:Financial Performance:CureVac reported solid cash position of €402.5 million at the end of 2023 and expects to ex
CureVac N.V. Reports Strong 2023 Finances and Strategic Advances
CureVac Launches Study for H5N1 Influenza Vaccine
CureVac Names New Chief Business Officer
Analysts' Opinions Are Mixed on These Healthcare Stocks: Boston Scientific (BSX) and CureVac (CVAC)
CureVac Shares Touch All-Time Low After Germany Deal Ends, Redesign News
By Stephen Nakrosis Shares of biopharmaceutical company CureVac touched a new low on Wednesday following news the company, together with GSK, ended a pandemic agreement with Germany and will implemen
CureVac Begins Early Stage Portion of Investigational Vaccine Trial
CureVac (CVAC) said Wednesday it initiated the early stage portion of a broader study into an investigational flu vaccine developed with GSK (GSK). The phase 1 trial is part of a combined phase 1/2 st
CureVac Hires New Chief Business Officer
German biopharmaceutical company CureVac (5CV.F) named Thaminda Ramanayake its new chief business officer, effective June 1. Ramanayake recently served as Affini-T Therapeutics' business chief, accord
CureVac Shares Are Trading Lower After the Company Reported Q4 Financial Results and Provided Business Updates.
CureVac Shares Are Trading Lower After the Company Reported Q4 Financial Results and Provided Business Updates.
Analysis
Price Target
No Data
